Consolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up

Wojciech Jurczak, Alicja M. Gruszka, Anna Sowa Staszczak, Monika Dlugosz-Danecka, Marta Szostek, Dagmara Zimowska-Curylo, Agnieszka Giza, Katarzyna Krawczyk, Malgorzata Jakobczyk, Alicja Hubalewska-Dydejczyk, Michal Szymczyk, Tomasz Wróbel, Wanda Knopińska-Posłuszny, Elżbieta Kisiel, Aleksander Skotnicki, Pier Luigi Zinzani

Research output: Contribution to journalArticle

Abstract

Polish Lymphoma Research Group performed a phase-II trial to test whether 90Y ibritumomab tiuxetan radioimmunotherapy (Y90) may constitute an alternative consolidation for mantle cell lymphoma patients unfit for high-dose therapy. Forty-six patients were consolidated with Y90 following response to the 1st (n = 34) or 2nd line (n = 12) (immuno)chemotherapy. Majority of the patients had advanced disease (stage IV and presence of B-symptoms in 85% and 70%, respectively) and high MIPI (5.8, range 4–7). Consolidation with Y90 increased the complete remission (CR) rate obtained by the 1st line therapy from 41% to 91% and allowed for median PFS of 3.3 and OS of 6.5 years. In the first relapse, CR rate increased from 16% to 75%, while median PFS and OS totaled 2.2 and 6.5 years, respectively. At 8 years, 30% of patients, consolidated in the 1st line CR were alive, without relapse. Toxicity associated with Y90 is manageable, more severe after fludarabine-based regimens.

Original languageEnglish
Pages (from-to)2689-2696
Number of pages8
JournalLeukemia and Lymphoma
Volume60
Issue number11
DOIs
Publication statusPublished - Sep 19 2019

Keywords

  • ibritumomab tiuxetan
  • Mantle cell lymphoma
  • radioimmunotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Consolidation with <sup>90</sup>Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up'. Together they form a unique fingerprint.

  • Cite this

    Jurczak, W., Gruszka, A. M., Sowa Staszczak, A., Dlugosz-Danecka, M., Szostek, M., Zimowska-Curylo, D., Giza, A., Krawczyk, K., Jakobczyk, M., Hubalewska-Dydejczyk, A., Szymczyk, M., Wróbel, T., Knopińska-Posłuszny, W., Kisiel, E., Skotnicki, A., & Zinzani, P. L. (2019). Consolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up. Leukemia and Lymphoma, 60(11), 2689-2696. https://doi.org/10.1080/10428194.2019.1602261